reports
- Sean Conroy
Midatech Pharma - Pivoting its commercial strategy
Midatech is a drug-delivery technology company focused on re-engineering existing therapeutics to improve their bioavailability and delivery. A strategic review in 2020 has translated into a broadened pipeline with the Q Sphera platform at its core (polymer microsphere technology for sustained drug release). The most clinically advanced asset is the Phase II ready MTX110 (MidaSolve platform, which liquifies insoluble oral therapies for improved drug delivery) targeting brain cancers such as diff...
1 director bought
A director at Midatech Pharma bought 450,000 shares at 6.8p and the significance rating of the trade was 63/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly s...
Midatech Announces Proposed Sale of Midatech Pharma US Inc. (“MTP US...
Midatech Announces Proposed Sale of Midatech Pharma US Inc. (“MTP US”) to Kanwa Holdings, LP an affiliate of Barings LLC 27 September 2018 Midatech Pharma PLC ("Midatech" or the "Company") Midatech Announces Proposed Sale of Midatech Pharma US Inc. (“MTP US”) to Kanwa Holdings, LP an affiliate of Barings LLC Total consideration of up to $19m, as initial consideration of $13 million and up to $6 million payable based on MTP US net sales performance in 2018 and 2019Midatech will, subject to completion of the Sale, become a pure-play R&D company focused on driving its technologies to deliv...
Midatech Announces Interim Results from Proof of Concept Exploratory S...
Midatech Announces Interim Results from Proof of Concept Exploratory Study for its MTD201 Q-Octreotide Programme and Q-Sphera™ Microsphere Technology 31 August 2018 Midatech Pharma PLC("Midatech" or the "Company") Midatech Announces Interim Results from Proof of Concept Exploratory Study for its MTD201 Q-Octreotide Programme and Q-Sphera™ Microsphere Technology Interim data for key oncology drug candidate MTD201 establishes favourable clinical profile compared to reference product Novartis’ Sandostatin® LAR® (“SLAR”)Drug-release properties of MTD201 distinct from SLAR Provide...
Midatech Pharma PLC: Trading Update
Midatech Pharma PLC: Trading Update 25 July 2018 Midatech Pharma PLC(“Midatech”, “Company” or “Group”) Trading Update Midatech Pharma (AIM: MTPH, Nasdaq: MTP), the international specialty pharmaceutical company focused on developing and commercialising products in oncology and immunotherapy, today announces a trading update for the six months ended 30 June 2018. The Company remains on track to deliver financial results in line with market expectations for FY18. For the six months to June 2018, the Board expects total gross product revenues of approximately £5.8 million, a 16% increas...
Midatech Pharma US announces Co-Promotion Agreement with Bausch Health...
Midatech Pharma US announces Co-Promotion Agreement with Bausch Health Companies Inc. for the Exclusive Right to Promote NeutraSal® to the Oncology Market in United States 23 July 2018 Midatech Pharma PLC(“Midatech”, “Company” or “Group”) Midatech Pharma US announces Co-Promotion Agreement with Bausch Health Companies Inc. for the Exclusive Right to Promote NeutraSal® to the Oncology Market in United States NeutraSal indicated for Xerostomia, a highly prevalent cancer treatment side effectMidatech anticipates commencing promotional activities in August Midatech Pharma (AIM: MTPH, Nasdaq...
Midatech Pharma US enrols first patient in Gelclair trial in stem cell...
Midatech Pharma US enrols first patient in Gelclair trial in stem cell transplant 8 June 2018 Midatech Pharma PLC(“Midatech”, “Company” or “Group”) Midatech Pharma US enrols first patient in Gelclair® trial in stem cell transplant Patients now being enrolled at the Dana-Farber/Brigham and Women’s Cancer Center and Massachusetts General Hospital Midatech Pharma (AIM: MTPH, Nasdaq: MTP), the international specialty pharmaceutical company focussed on developing and commercialising products in oncology and immunotherapy, today announces that, further to the Group’s announcement dated 20...
- Riccardo Lowi
Capital Network: Midatech Pharma PLC - Addressing high unmet need in c...
A fully integrated specialty pharma company, Midatech Pharma is rapidly progressing the development of three lead R&D programs. They have developed three proprietary drug delivery technologies (Q-Sphera, Gold Nano Particle and Nano Inclusion) to improve and expand the therapeutic potential of validated drug products. At the same time Midatech has built a US commercial unit focused on supportive care products.
Ford Equity International Rating and Forecast Report
Ford Equity International Research Reports cover 60 countries with over 30,000 stocks traded on international exchanges. A proprietary quantitative system compares each company to its peers on proven measures of business value, growth characteristics, and investor behavior. Ford's three recommendation ratings buy, hold and sell, represent each stock’s return potential relative to its own country market.. The rating reports which are generated each week, include the fundamental details behind...
ADR Update: DARA - acquiring US presence in oncology
Midatech closed its all-share acquisition of DARA BioSciences on 7 December (first announced in June), thereby acquiring a presence in the US oncology market via DARA’s 20-strong sales force and portfolio of marketed cancer support products. On 18 December, Midatech announced the acquisition of anti-emetic drug, Zuplenz (from Galena, for $3.75m), a strong fit with DARA’s existing anti-cancer support products. The new Midatech shares are listed as ADRs on NASDAQ on the back of its recent IPO ...
Update: DARA - acquiring US presence in oncology
Midatech closed its all-share acquisition of DARA BioSciences on 7 December (first announced in June), thereby acquiring a presence in the US oncology market via DARA’s 20-strong sales force and portfolio of marketed cancer support products. On 18 December, Midatech announced the acquisition of anti-emetic drug, Zuplenz (from Galena, for $3.75m), a strong fit with DARA’s existing anti-cancer support products. The new Midatech shares are listed as ADRs on NASDAQ on the back of its recent IPO ...
Update: Buccal strip insulin starts Phase IIa diabetes trial
Midatech has announced that the first patient in the Phase IIa study for its transbuccal insulin (MSL-001) has been treated. MSL-001 is the lead programme from the gold nanoparticle (GNP) platform and represents the largest element within our rNPV model, valued at £67.3m (242p a share). Our rNPV model, excluding the proposed DARA BioSciences acquisition, suggests a current value of £134.7m (485p a share).
Initiation: Golden moments
Midatech is a clinical-stage development company. Its two core technology platforms have broad applicability, offering the potential to transform the bioavailability and delivery of many existing therapeutic agents. The gold nanoparticle (GNP) platform underpins a number of clinical programmes, with the lead project being the transbuccal delivery of insulin. The polymer microsphere technology can tailor a drug’s release over extended periods. Management is proposing to acquire DARA BioSciences...
QuickView: A golden ticket
Midatech is developing a portfolio of innovative medicines using its proprietary technology platforms. These employ gold nanoparticles to enhance and tailor the pharmacokinetics of proven molecules for diabetes, oncology and neurological indications. An additional polymer technology allows the control of release rates, potentially extending therapeutic activity to several months. The £32m (gross) raised in the IPO means it is funded to progress its pipeline to a number of value inflection point...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.